A stapled peptide (EHBI2) designed to mimic the H-helix of the EGFR kinase domain successfully disrupted EGFR dimerization and signaling in cancer cells — the first compound to target this allosteric interface.
First-in-Class Allosteric EGFR PeptideEHBI2 is the first compound to successfully target the asymmetric kinase dimer interface of EGFR, offering a resistance-proof alternative to active site inhibitors
What the researchers found
The stapled peptide EHBI2, designed to mimic the H-helix of the EGFR kinase domain, successfully disrupted the asymmetric kinase dimer interface required for EGFR activation. Peptide stapling notably enhanced cell permeation compared to the unconstrained version.
In cell-based assays, EHBI2 significantly reduced EGFR phosphorylation (the marker of EGFR activation) and phosphorylation of the downstream signaling substrate Akt, confirming disruption of the entire EGFR signaling cascade. This is the first H-helix-based compound targeting the asymmetric dimer interface of the EGFR kinase domain that can successfully inhibit EGFR activation and signaling.
Why it matters
Drug resistance is the Achilles' heel of EGFR-targeted cancer therapy — mutations in the active site render current inhibitors ineffective. By targeting a completely different site on EGFR (the allosteric dimer interface), this stapled peptide approach could work even when conventional drugs fail. If developed further, allosteric EGFR inhibitors could provide a new treatment option for patients with resistant lung cancer, head and neck cancer, and other EGFR-driven malignancies.
How the study worked
A library of constrained peptides was designed to mimic the H-helix of the EGFR kinase domain, with interface side chains optimized through molecular modeling. Peptides were constrained using hydrocarbon stapling to reinforce alpha-helical conformation. Cell permeation was assessed by fluorescence microscopy. EGFR inhibition was measured in tumor cell lines by monitoring EGFR phosphorylation and Akt phosphorylation using cell-based assays.
What this study cannot tell us
All experiments were performed in cell-based assays, with no in vivo animal tumor model testing. The specific cancer cell lines used and the magnitude of EGFR inhibition were not quantified in the abstract. Pharmacokinetic properties (stability in blood, half-life) of the stapled peptide are unknown. Manufacturing scalability was not addressed. The study did not compare EHBI2's efficacy to existing EGFR inhibitors or test it against resistance mutations.
How to read the evidence
This is an early-stage preclinical proof-of-concept study with in vitro cell-based assays only. While it demonstrates a novel targeting approach with clear mechanistic validation, no animal models or clinical data exist yet. This represents the earliest stage of drug discovery evidence.
When this study was published
Published in 2018, this study established the feasibility of targeting the EGFR dimer interface with stapled peptides. The concept has since informed ongoing research into allosteric kinase inhibitors and peptide-based cancer therapeutics.
The bigger picture
This study is part of the broader movement toward allosteric drug design — targeting regulatory sites rather than active sites to overcome resistance. Stapled peptides are uniquely suited for disrupting protein-protein interfaces like the EGFR dimer, which are traditionally considered 'undruggable' by small molecules. The success of EHBI2 validates the concept that kinase dimer interfaces can be targeted by peptide therapeutics, opening this approach to other kinase targets in cancer.
Questions still open
- Does EHBI2 retain its ability to inhibit EGFR in cells carrying resistance mutations that render current inhibitors ineffective?
- Could this allosteric peptide approach be combined with conventional EGFR inhibitors to prevent or overcome resistance?
- Can the H-helix targeting strategy be adapted for other receptor tyrosine kinases that use similar dimer activation mechanisms?
Common questions
Why do cancer drugs that target EGFR stop working?
What makes stapled peptides good for targeting protein interfaces?
Read the original research
Conformationally constrained peptides target the allosteric kinase dimer interface and inhibit EGFR activation.
Bioorganic & medicinal chemistry, 26(6), 1167-1173
Citation
Fulton, Melody D; Hanold, Laura E; Ruan, Zheng; Patel, Sneha; Beedle, Aaron M; Kannan, Natarajan; Kennedy, Eileen J. (2018). Conformationally constrained peptides target the allosteric kinase dimer interface and inhibit EGFR activation.. Bioorganic & medicinal chemistry, 26(6), 1167-1173. https://doi.org/10.1016/j.bmc.2017.08.051